Acute myeloid leukemia is a fast-growing cancer that starts in the bone marrow—the soft center of bones where blood cells are made. In AML, early myeloid cells (immature “blasts”) stop maturing and multiply out of control. These blasts crowd out healthy cells, causing anemia (low red cells), infections (low white cells), and bleeding or bruising (low platelets). AML can arise “de novo” (with no known earlier problem), from a prior bone-marrow disorder like myelodysplastic syndrome (MDS), or after past chemotherapy or radiation (“therapy-related” AML). Doctors diagnose AML with blood tests, bone-marrow biopsy, and genetic testing of leukemia cells to find key mutations (e.g., FLT3, IDH1/IDH2). These mutations help guide targeted therapies. Treatment is urgent because AML progresses quickly, but many people achieve remission with modern chemotherapy, targeted drugs, clinical trials, and sometimes stem-cell transplantation. “Acute” means it grows fast; “myeloid” refers to the cell type; “leukemia” means cancer of blood-forming tissues. Other names include “acute myelogenous,” “acute myelocytic,” or simply “AML.”
Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow. It starts from very early cells that normally mature into myeloid white blood cells, red blood cells, or platelets. In AML, these early cells (called “blasts”) get stuck in an immature state. They multiply quickly and crowd out normal blood-forming cells. Because of this, the body cannot make enough healthy red cells to carry oxygen, platelets to control bleeding, or white cells that fight infection.
AML develops in the bone marrow, which is the soft tissue inside bones where blood cells are made. Cancer cells spill into the blood and can travel to the liver, spleen, gums, skin, brain coverings, and other organs. Doctors usually diagnose AML when blasts make up 20% or more of cells in the marrow or blood, or when certain leukemia-specific genetic changes are present. AML is a medical emergency in some cases, especially when white counts are extremely high or when a special type called acute promyelocytic leukemia causes dangerous blood-clotting problems.
AML can appear “out of the blue” (de novo) or after a previous bone marrow disease, such as myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN). It can also occur after prior chemotherapy or radiation used to treat another cancer. Many gene changes drive AML. Some gene changes are used to confirm the diagnosis, estimate risk, and choose treatment, because certain drugs work better in AML with specific targets. Treatment is usually given in the hospital. It often starts with strong “induction” chemotherapy to clear blasts, followed by more therapy to keep leukemia from returning. Stem cell transplant may be advised for higher-risk disease. Supportive care is vital: antibiotics, blood products, and measures to prevent bleeding and tumor lysis.
Other names
AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, or acute non-lymphocytic leukemia (ANLL). Older names include acute granulocytic leukemia and acute myelocytic leukemia. A special subtype is acute promyelocytic leukemia (APL), caused by the PML::RARA fusion gene. Another family of terms you may see are de novo AML (newly arisen), secondary AML (develops from MDS/MPN), and therapy-related AML (after chemo or radiation). All these names point to a fast-growing cancer of myeloid blood-forming cells.
Types of AML
There are many ways to group AML. Doctors use how the leukemia looks under the microscope, which genes are changed, and the setting in which AML appears.
1) De novo AML.
AML that starts without a known bone marrow disease or prior chemo/radiation. It is the most common starting point in adults. Gene tests still guide risk and treatment.
2) Secondary AML (from MDS or MPN).
AML that grows out of a long-standing bone marrow disorder such as myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN). It often carries higher-risk gene changes and may need more intensive therapy or transplant.
3) Therapy-related AML (t-AML).
AML that develops after chemotherapy, radiation, or both for a different cancer. Typical causes include prior exposure to alkylating agents, topoisomerase II inhibitors, or high-dose radiation. It often has complex chromosome changes and a tougher course.
4) AML with t(8;21) (RUNX1::RUNX1T1).
A “core-binding factor” leukemia. Often has large blasts with Auer rods. It can respond well to standard therapy but needs careful genetic follow-up.
5) AML with inv(16) or t(16;16) (CBFB::MYH11).
Another core-binding factor leukemia. Often shows abnormal eosinophils on smear. Usually has a good response to modern treatment.
6) Acute Promyelocytic Leukemia (APL, PML::RARA).
A unique emergency subtype. It causes severe bleeding or clotting because of a DIC-like state. It is highly curable with targeted non-chemotherapy drugs (all-trans retinoic acid and arsenic trioxide) if started quickly.
7) AML with mutated NPM1.
Common in adults. Often shows high white count and “cup-shaped” nuclei on smear. Prognosis varies and is influenced by other mutations such as FLT3.
8) AML with biallelic CEBPA mutations.
Often presents with normal chromosomes and has a relatively favorable outlook when both copies of the CEBPA gene are mutated.
9) AML with FLT3 mutation (ITD or TKD).
FLT3 drives rapid cell growth. Targeted FLT3 inhibitors are added to chemotherapy and can be used later if the leukemia returns.
10) AML with IDH1 or IDH2 mutations.
These mutations create an abnormal metabolite (2-HG) that blocks normal cell maturation. Oral IDH inhibitors can help blasts mature and die.
11) AML with inv(3)/t(3;3) (GATA2/MECOM).
A higher-risk leukemia that needs careful planning; transplant is often considered.
12) AML with KMT2A (MLL) rearrangements.
Seen in both children and adults. Often requires intensive care plans and possible transplant.
13) AML with myelodysplasia-related changes (AML-MR).
Defined by specific history (prior MDS/MPN), distinct chromosome changes, or gene mutations linked to MDS biology (for example, ASXL1, SRSF2, SF3B1). Usually higher risk.
14) FAB M0–M7 (older system).
This older French-American-British system classifies AML by cell appearance: M0 (minimally differentiated) through M7 (megakaryoblastic). It is still used for quick clinical descriptions but has been largely replaced by genetics-based systems.
15) Myeloid sarcoma (granulocytic sarcoma).
A solid “tumor-like” mass of myeloid blasts in tissues such as skin, bone, or lymph nodes. It is treated like AML, even if blood and marrow show few blasts at first.
Causes and risk factors
1) Older age.
AML risk rises with age because bone marrow cells collect more gene damage over time. Most adult cases occur after age 60.
2) Male sex.
Men have a slightly higher risk than women for reasons that are not fully known.
3) Smoking.
Cigarette smoke contains benzene and other chemicals that harm marrow DNA. Smoking increases AML risk in adults.
4) Benzene and solvent exposure.
Long-term exposure to benzene (in some industries, fuels, or solvents) can injure marrow stem cells and raise AML risk.
5) Prior chemotherapy.
Past treatment with alkylating agents or topoisomerase II inhibitors can damage marrow DNA and lead to therapy-related AML years later.
6) Prior radiation therapy or high-dose radiation exposure.
Radiation can cause DNA breaks in marrow cells that later become leukemia.
7) Prior myelodysplastic syndrome (MDS).
MDS can progress to AML as abnormal clones gain more mutations and outgrow normal cells.
8) Prior myeloproliferative neoplasm (MPN).
Diseases like polycythemia vera, essential thrombocythemia, or myelofibrosis can transform into AML.
9) Inherited RUNX1 disorder (familial platelet disorder).
People born with a damaged RUNX1 gene have low platelets and a high chance of AML later in life.
10) Inherited CEBPA mutation.
A familial CEBPA change raises the chance of AML, often at younger ages.
11) GATA2 deficiency.
An inherited immune and marrow disorder that increases the risk of MDS/AML.
12) Down syndrome (Trisomy 21).
Children with Down syndrome have a higher risk of certain acute leukemias, including AML (especially the megakaryoblastic type).
13) Fanconi anemia and DNA repair syndromes.
Inherited problems in DNA repair (Fanconi anemia, Bloom syndrome, ataxia telangiectasia) raise leukemia risk.
14) Li-Fraumeni syndrome (TP53).
A germline TP53 change leads to many cancers, including AML in some families.
15) Neurofibromatosis type 1.
This condition can be linked with childhood leukemias and other tumors.
16) Dyskeratosis congenita and telomere disorders.
Short telomeres impair marrow cell renewal and can lead to MDS/AML.
17) Obesity.
Extra body fat may drive chronic inflammation and hormonal changes that increase AML risk.
18) Long-term pesticide or agricultural chemical exposure.
Some studies link chronic exposure to higher leukemia risk, though the strength of the link varies.
19) Clonal hematopoiesis (CHIP).
With age, some people develop small clones of marrow cells with mutations (DNMT3A, TET2, ASXL1). Most never get AML, but the risk is higher than normal.
20) Family history of blood cancers.
Having close relatives with myeloid cancers can reflect shared genes or shared exposures that increase AML risk.
Symptoms and signs
1) Fatigue and weakness.
Low red blood cells (anemia) mean less oxygen gets to tissues. People feel tired, weak, or short of breath with simple tasks.
2) Pale skin.
Anemia causes a pale look of the skin, lips, and nail beds.
3) Shortness of breath.
Low red cell counts and very high white counts reduce oxygen delivery and blood flow in small vessels.
4) Frequent infections.
Leukemia blasts do not fight germs. Normal white cells are low, so infections happen often or last longer.
5) Fever and chills.
Fever can be due to infection or due to the leukemia itself releasing inflammatory signals.
6) Easy bruising.
Low platelets cause bruises to appear after minor bumps or even without clear injury.
7) Bleeding gums or nosebleeds.
Platelet shortage and clotting problems cause gum bleeding when brushing teeth, nosebleeds, or prolonged bleeding from small cuts.
8) Tiny red spots on skin (petechiae).
These pin-point dots show bleeding under the skin from very low platelets.
9) Bone or joint pain.
Crowded marrow and swift blast growth stretch the bone lining and cause pain or aching.
10) Fullness or pain under left ribs.
The spleen can enlarge when it filters many abnormal cells, causing discomfort or fullness.
11) Swollen gums.
Certain AML types (monocytic forms) can infiltrate the gums, making them thick and tender.
12) Skin changes or lumps (leukemia cutis).
Blasts can collect in the skin, forming red or purple patches or nodules.
13) Headache, confusion, or vision changes.
Very high white counts can slow blood flow in small brain or eye vessels (leukostasis). Bleeding can also cause symptoms.
14) Night sweats and weight loss.
Fast-growing cancer uses energy and releases inflammatory signals that cause sweats and weight loss.
15) Infections that do not improve.
Pneumonia, urinary infections, or mouth infections may be hard to clear because immune function is weak.
Diagnostic tests
A) Physical examination (observations and bedside checks)
1) General exam with vital signs.
Doctors look for fever, high heart rate, low blood pressure, and breathing problems. These can signal infection, dehydration, or leukostasis.
2) Skin and mucosa check for bleeding.
Bruises, petechiae, and gum bleeding suggest low platelets or clotting problems, which are common in AML.
3) Lymph node and organ exam.
Doctors gently feel the neck, armpits, and groin for nodes, and check liver and spleen size. Some AML cases enlarge these organs.
4) Oral cavity and gum inspection.
Swollen, tender gums or mouth sores point toward monocytic AML or infection due to low white cells.
5) Neurologic and eye (fundus) exam.
Headache, confusion, unequal pupils, or retinal bleeding can point to leukostasis, bleeding, or infection that needs urgent care.
B) Manual tests (simple bedside procedures and assessments)
6) Capillary refill and peripheral perfusion check.
Pressing on a fingernail and watching the pink color return helps judge circulation, which can be poor with sepsis or very high counts.
7) Orthostatic blood pressure and pulse.
Measuring standing and lying pressures helps detect dehydration or blood loss from bleeding.
8) Stool guaiac (fecal occult blood) card.
This bedside chemical card can detect hidden intestinal bleeding when platelets are very low.
9) Spleen and liver percussion/palpation techniques.
Percussion (tapping) and gentle pressing check organ size more precisely, guiding imaging and labs.
10) Bedside infection screens (throat, wound, catheter).
Targeted swabs and quick antigen tests help find infection sources in immunocompromised patients.
C) Laboratory and pathological tests (core to diagnosis)
11) Complete blood count (CBC) with differential.
This key test measures red cells, white cells, and platelets. It often shows anemia, thrombocytopenia, and circulating blasts.
12) Peripheral blood smear review.
A pathologist looks under the microscope for blasts, Auer rods, irregular nuclei, and abnormal granules. This supports the diagnosis and guides urgent steps.
13) Bone marrow aspiration.
A liquid marrow sample from the hip bone is examined for blast percentage, cell details, and basic stains. It confirms AML and sets a baseline.
14) Bone marrow core biopsy.
A small cylinder of bone shows the architecture of marrow, fibrosis, and how blasts are arranged. It complements the aspiration.
15) Flow cytometry immunophenotyping.
This test uses antibodies to define which markers are on the blast surface (e.g., CD34, CD117, MPO). It distinguishes AML from other leukemias and subtypes.
16) Cytogenetics (karyotype) and FISH.
Chromosome studies find translocations and gains/losses (e.g., t(8;21), inv(16), t(15;17)). FISH is faster for specific targets.
17) Molecular testing (PCR/NGS panels).
Detects gene mutations such as NPM1, FLT3, CEBPA, IDH1/2, TP53, KIT, and splicing genes. Results guide prognosis and targeted therapy choices.
18) Coagulation profile (PT/INR, aPTT, fibrinogen, D-dimer).
Screens for DIC, especially in APL, and helps manage bleeding/clotting risks.
19) Chemistry and tumor lysis labs (electrolytes, uric acid, LDH, creatinine, phosphorus, calcium).
These identify kidney strain and tumor lysis risk before and during treatment.
20) HLA typing (when transplant is considered).
A blood test that matches immune proteins to find a stem cell donor for higher-risk AML or relapse.
(Note on electrodiagnostic and imaging: Although not always counted among the “core 20,” doctors also use supportive tests such as an ECG to check heart rhythm/QT before some drugs, and imaging like a chest X-ray or brain CT/MRI if infection, leukostasis, or bleeding is suspected.)
D) Electrodiagnostic tests (supportive, when indicated)
ECG (electrocardiogram).
Checks heart rhythm and QT interval before drugs that can affect the heart (for example, arsenic trioxide in APL) and during sepsis or electrolyte shifts.
EEG (electroencephalogram) if seizures or altered state.
Used when AML or infections affect the brain. It helps rule out seizure activity and guides therapy.
E) Imaging tests (used based on symptoms)
Chest X-ray or chest CT.
Looks for pneumonia, fungal infections, fluid overload, or lines/tubes position in immunocompromised patients with fever or breathing issues.
Brain CT or MRI.
Ordered if there is headache, confusion, weakness, or vision changes to detect bleeding, stroke from leukostasis, or infection.
Non-Pharmacological Treatments
(15 Physiotherapy + Mind-Body & Gene-Informed + Educational & Self-Management)
Important: Non-drug strategies do not treat cancer cells, but they support strength, safety, quality of life, and treatment tolerance. Always clear any activity with your care team, especially during low-blood-count periods.
A) Physiotherapy
-
Gentle walking (intervals indoors or on a treadmill)
Description (≈150 words): Short, frequent indoor walks are a safe way to keep your legs, lungs, and heart active during treatment. Begin with 3–5 minutes, several times per day, and pause if you feel dizzy, short of breath, or unusually tired. If counts are low or if you’re on neutropenic precautions, walk in clean indoor spaces. Wear supportive shoes and avoid trip hazards. Over time, you can add brief “intervals”—30–60 seconds slightly faster—followed by easy walking.
Purpose: Maintain endurance and reduce deconditioning.
Mechanism: Mild aerobic activity improves circulation, mitochondrial activity, and muscle efficiency.
Benefits: Better energy, mood, sleep, and appetite; less stiffness. -
Seated leg and arm strengthening with resistance bands
Description: Use light bands to work large muscle groups while seated (leg press-outs, biceps curls, rows). Do 1–2 sets of 8–12 reps, 3–4 days per week, resting if fatigued.
Purpose: Preserve muscle mass and function.
Mechanism: Resistance stimulates muscle protein synthesis.
Benefits: Improved ability to stand, climb steps, and carry items. -
Sit-to-stand practice (chair squats)
Description: From a sturdy chair, cross arms over chest and stand up slowly; sit down with control. Start with 5 reps, up to 2–3 sets.
Purpose: Maintain independence for daily tasks.
Mechanism: Trains quadriceps, glutes, core control.
Benefits: Safer transfers, better balance, less fall risk. -
Ankle pumps and calf raises
Description: Point and flex the ankles; then do supported heel raises.
Purpose: Prevent swelling and blood stasis with low activity.
Mechanism: Muscle pumping supports venous return.
Benefits: Less ankle edema; more ankle strength. -
Gentle shoulder mobility (pendulums, wall slides)
Description: Light shoulder circles, wall-assisted slides, and pendulum swings.
Purpose: Prevent stiffness from bed rest or lines.
Mechanism: Keeps joints lubricated and flexible.
Benefits: Easier dressing, reaching, and self-care. -
Core activation (abdominal bracing, pelvic tilts)
Description: While lying or seated, gently tighten abdominal wall; practice neutral spine with breathing.
Purpose: Protect posture and back during fatigue.
Mechanism: Low-load activation supports spinal stability.
Benefits: Less back discomfort; better balance. -
Balance drills (tandem stance, single-leg holds with support)
Description: Stand with one foot in front of the other while lightly holding a counter; progress to brief single-leg holds.
Purpose: Reduce falls.
Mechanism: Challenges proprioception safely.
Benefits: Confidence in walking and transfers. -
Diaphragmatic breathing with pacing
Description: Inhale through the nose (belly rises), exhale through pursed lips longer than the inhale.
Purpose: Ease shortness of breath and anxiety.
Mechanism: Improves ventilation efficiency; calms autonomic nervous system.
Benefits: More comfortable activity; better sleep. -
Gentle yoga (chair or bed-based)
Description: Simple poses (seated cat-cow, gentle twists) with breath. Avoid inversions or strain.
Purpose: Flexibility and relaxation.
Mechanism: Stretching and vagal tone support.
Benefits: Less stiffness; calmer mood. -
Stretching routine (hamstrings, hip flexors, chest)
Description: 20–30 seconds each, 1–2 times daily, no pain.
Purpose: Counteract immobility and bed rest.
Mechanism: Restores muscle length.
Benefits: Easier movement; less soreness. -
Hand-grip training
Description: Use a soft ball or putty; squeeze and release for 1–2 minutes.
Purpose: Maintain grip for self-care tasks.
Mechanism: Local muscle endurance.
Benefits: Better jar opening, utensil use. -
Step-up practice (low step with rail)
Description: Slow, supported step-ups; stop if dizzy.
Purpose: Functional leg power.
Mechanism: Concentric/eccentric quad work.
Benefits: Easier stairs, transfers. -
Posture resets
Description: Every hour, sit tall, roll shoulders back, chin tuck.
Purpose: Reduce neck and back strain.
Mechanism: Counteracts slouching.
Benefits: Less pain; better breathing mechanics. -
Energy conservation training
Description: Plan tasks for your best-energy time, sit for chores, cluster trips, rest before symptoms worsen.
Purpose: Stretch limited energy.
Mechanism: Matches activity to reserves.
Benefits: More control and less fatigue. -
Falls-proofing your space
Description: Clear clutter, add night lights, non-slip mats, sturdy footwear.
Purpose: Prevent injuries while counts are low.
Mechanism: Reduces environmental hazards.
Benefits: Safer home, fewer accidents.
B) Mind-Body & “Gene-Informed” Stress Modulation
-
Mindfulness meditation (10 minutes/day)
Description: Quiet breathing with non-judging awareness of thoughts and body sensations.
Purpose: Lower stress and rumination.
Mechanism: Calms sympathetic activity; may influence inflammatory signaling.
Benefits: Better sleep, mood, and coping. -
Guided imagery for procedures
Description: Listen to audio scripts before chemo or biopsy, imagining soothing scenes.
Purpose: Reduce anticipatory anxiety and pain.
Mechanism: Alters pain perception pathways.
Benefits: More comfort, less distress. -
Brief cognitive behavioral tools
Description: Challenge “all-or-nothing” thoughts; replace with realistic coping statements.
Purpose: Build resilience during long care.
Mechanism: Reframes stress appraisal.
Benefits: Improved adherence and life quality. -
Gratitude journaling (3 items nightly)
Description: Write three things that went well today.
Purpose: Balance difficult days with small wins.
Mechanism: Shifts attention patterns.
Benefits: Lower perceived stress; better mood. -
Music-assisted relaxation
Description: 15–20 minutes of calming music with slow breathing.
Purpose: Ease tension and nausea.
Mechanism: Modulates limbic/autonomic tone.
Benefits: Comfort, appetite, and rest.
C) Educational & Self-Management
-
Infection-prevention hygiene
Description: Handwashing, safe food handling, clean mouth care, and mask use in crowds as advised.
Purpose: Reduce infection risk when neutropenic.
Mechanism: Lowers pathogen exposure.
Benefits: Fewer setbacks and hospital visits. -
Medication calendar + symptom diary
Description: Track doses, side effects, temperatures, bleeding, and fatigue scores.
Purpose: Early problem detection.
Mechanism: Structured monitoring.
Benefits: Faster care team response. -
Safe-activity education
Description: What’s safe with a central line, when to pause exercise, how to lift safely.
Purpose: Prevent line issues and injuries.
Mechanism: Risk awareness.
Benefits: Fewer complications. -
Nutrition basics during treatment
Description: Emphasize protein, fluids, and food safety; small frequent meals.
Purpose: Preserve weight and healing capacity.
Mechanism: Supports nitrogen balance and hydration.
Benefits: Better strength and recovery. -
Care-partner training
Description: Teach helpers to check temperatures, watch for bleeding/bruising, and support appointments.
Purpose: Shared safety net.
Mechanism: Team awareness.
Benefits: Earlier action, less stress.
Drug Treatments
(Doses vary by protocol, age, kidney/liver function, and mutation status. Follow your oncologist’s exact plan.)
-
Cytarabine (Ara-C) — antimetabolite chemotherapy
Typical use/dose: In classic “7+3” induction, a continuous infusion is given for 7 days; in consolidation, “high-dose” cytarabine may be used in cycles (exact mg/m² per protocol).
Purpose: Kill rapidly dividing leukemia blasts.
Mechanism: Inhibits DNA synthesis (S-phase).
Common side effects: Low blood counts, mouth sores, nausea, hair loss; at high doses, coordination or vision problems—report any new neurological symptoms immediately. Cancer.govCanadian Cancer Society -
Daunorubicin — anthracycline chemotherapy
Typical use/dose: Given on days 1–3 alongside cytarabine (“7+3”); dose intensity varies (e.g., 60–90 mg/m²/day in some regimens).
Purpose: Achieve remission in induction.
Mechanism: Intercalates DNA and inhibits topoisomerase II.
Common side effects: Low counts, mouth sores, hair loss; heart effects with high cumulative dose—cardiac monitoring is standard. eviq.org.au -
Idarubicin — anthracycline chemotherapy
Typical use: Alternate to daunorubicin in 7+3; sometimes paired with midostaurin in FLT3-mutated AML.
Purpose/Mechanism/side effects: Similar to daunorubicin; dosing per protocol, cardiac monitoring required. Haematologica -
Mitoxantrone — anthracenedione chemotherapy
Use: Sometimes used in induction/salvage regimens.
Purpose: Additional cytotoxic option.
Mechanism: DNA intercalation/topoisomerase II inhibition.
Side effects: Myelosuppression, mucositis, cardiotoxicity (lower than anthracyclines but still monitored). -
CPX-351 (daunorubicin + cytarabine liposome, VYXEOS) — liposomal fixed-ratio chemo
Use/dose: Specific infusion schedule for induction/consolidation per label.
Purpose: Designed for therapy-related AML or AML with myelodysplasia-related changes.
Mechanism: Delivers drugs in a fixed synergistic ratio inside liposomes to bone marrow.
Side effects: Prolonged low counts, infections, bleeding, mouth sores; cardiac monitoring. FDA Access Data+1 -
Azacitidine — hypomethylating agent (HMA)
Use: With venetoclax for older/unfit patients; sometimes alone or in maintenance settings.
Purpose: Reduce blast burden by re-activating silenced genes and triggering cell death.
Mechanism: DNA methyltransferase inhibitor.
Side effects: Low counts, nausea, fatigue, injection-site reactions. U.S. Food and Drug AdministrationPMC -
Decitabine — HMA
Use: Similar to azacitidine; often paired with venetoclax when intensive chemo isn’t suitable.
Purpose/Mechanism: Demethylation restoring gene expression; promotes apoptosis.
Side effects: Myelosuppression, infections, fatigue. U.S. Food and Drug Administration -
Venetoclax — BCL-2 inhibitor (targeted)
Use/dose: Combined with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed older/unfit adults; daily schedules vary (7–28 days/cycle in studies; your team sets the exact plan).
Purpose: Prime leukemia cells for apoptosis.
Mechanism: Blocks BCL-2, allowing cancer cells to undergo programmed death.
Side effects: Low counts, infections, tumor lysis risk—close monitoring is required when starting. U.S. Food and Drug AdministrationPMCNature -
Midostaurin — FLT3 inhibitor (targeted)
Use: Added to 7+3 and consolidation for newly diagnosed FLT3-mutated AML; also used as maintenance in some protocols.
Mechanism: Inhibits mutant FLT3 signaling.
Side effects: Nausea, vomiting, mouth sores, low counts; QT monitoring may be used. PMCASH Publications -
Gilteritinib — FLT3 inhibitor (targeted)
Use/dose: 120 mg orally once daily for relapsed/refractory FLT3-mutated AML.
Mechanism: Blocks FLT3 signaling that drives blast growth.
Side effects: Liver enzyme elevations, fatigue, diarrhea, differentiation syndrome—urgent evaluation if fevers, shortness of breath, or rapid weight gain occur. U.S. Food and Drug AdministrationPMCNew England Journal of Medicine -
Ivosidenib — IDH1 inhibitor (targeted)
Use: For IDH1-mutated AML (newly diagnosed in specific settings, and relapsed/refractory); oral daily dosing per label.
Mechanism: Blocks mutant IDH1, reducing 2-HG, allowing cells to mature.
Side effects: Differentiation syndrome, QT prolongation, fatigue; careful monitoring is essential. FDA Access Datatibsovo.com -
Enasidenib — IDH2 inhibitor (targeted)
Use/dose: 100 mg orally once daily for IDH2-mutated relapsed/refractory AML.
Mechanism: Inhibits mutant IDH2, reduces 2-HG, promotes differentiation.
Side effects: Differentiation syndrome, indirect hyperbilirubinemia, GI upset—report early. PMCU.S. Food and Drug Administration -
Gemtuzumab ozogamicin (GO) — anti-CD33 antibody-drug conjugate
Use: In selected CD33-positive AML, either combined with chemo (newly diagnosed) or as a single-agent in relapse, following dosing schedules per label.
Mechanism: Delivers a cytotoxic agent directly to CD33-expressing blasts.
Side effects: Low counts, infusion reactions, and rare liver veno-occlusive disease—close monitoring is standard. FDA Access DataPfizer LabelingPMC -
Glasdegib — Hedgehog pathway inhibitor
Use/dose: 100 mg orally once daily in combination with low-dose cytarabine for older/unfit newly diagnosed AML.
Mechanism: Inhibits Hedgehog signaling linked to leukemic stem-cell survival.
Side effects: Anemia, fatigue, mouth sores, taste change; ECG and interactions reviewed by the team. U.S. Food and Drug AdministrationPMCDaurismo -
Hydroxyurea (supportive cytoreduction)
Use: Short-term oral cytoreduction to quickly lower very high white counts before/while definitive therapy begins; dosing individualized.
Mechanism: Inhibits DNA synthesis to reduce blast burden.
Side effects: Low counts, mouth sores; used as a temporary bridge in hyperleukocytosis policies alongside fluids and TLS prevention. PMC
Dietary “Molecular” Supplements
Supplements can interact with chemotherapy and targeted drugs. Many people should not take extra supplements unless a deficiency is proven. Safety first.
-
Vitamin D (if deficient) — Typical dose: per level, often 800–2000 IU/day (or repletion plan).
Function: Bone, muscle, immune support.
Mechanism: Nuclear receptor signaling that may modulate immunity.
Note: Check levels; avoid excess. -
Omega-3 fatty acids (EPA/DHA) — Dose: commonly 1–2 g/day combined EPA/DHA if approved.
Function: Anti-inflammatory support, possible appetite/muscle benefits.
Mechanism: Membrane lipid signaling; eicosanoid balance.
Caution: Bleeding risk with thrombocytopenia—ask your team. -
Whey protein or medical nutrition shakes — Dose: 20–30 g protein serving as advised.
Function: Maintain lean mass and healing.
Mechanism: Provides essential amino acids (leucine) for protein synthesis.
Note: Choose pasteurized, safely prepared products. -
Oral glutamine (for mucositis—evidence mixed) — Dose: protocol-guided.
Function: May support gut lining integrity.
Mechanism: Fuel for enterocytes and immune cells.
Caution: Discuss with oncology—studies vary. -
Zinc (if deficient) — Dose: only to correct deficiency.
Function: Taste, wound healing, immunity.
Mechanism: Cofactor for enzymes and transcription factors.
Caution: Too much can lower copper and immunity. -
Selenium (if deficient) — Dose: per labs.
Function: Antioxidant enzyme cofactor.
Mechanism: Glutathione peroxidase activity.
Caution: Excess is harmful; avoid on your own. -
Folate/B12 (if deficient) — Dose: per labs and oncology advice.
Function: DNA synthesis; corrects deficiency anemia.
Mechanism: One-carbon metabolism.
Caution: Only if deficient, because AML therapy targets DNA synthesis. -
Electrolyte mixes (as approved) — Dose: per hydration plan.
Function: Replace sodium/potassium losses from nausea/diarrhea.
Mechanism: Supports fluid balance and nerve/muscle function.
Caution: Kidney function and lab values guide use. -
Thiamine (if malnourished/at risk) — Dose: as prescribed.
Function: Energy metabolism; prevents deficiency.
Mechanism: Coenzyme in carbohydrate metabolism.
Note: Often used in poor intake or alcohol use. -
Probiotics: generally avoid during neutropenia
Reason: Rare but serious bloodstream infections have been reported. Focus on safe food handling instead; ask your team.
Immunity/Regenerative/Stem-Cell–Related” Drugs
-
Filgrastim (G-CSF) — Typical dose: ~5 mcg/kg/day subcutaneously after chemotherapy until neutrophil recovery.
Function: Boosts neutrophil production to reduce duration of neutropenia.
Mechanism: Stimulates myeloid progenitors in marrow. -
Pegfilgrastim (long-acting G-CSF) — Dose: single fixed dose per cycle as directed.
Function/Mechanism: Same as G-CSF with longer half-life.
Note: Timing relative to chemo is important. -
Sargramostim (GM-CSF) — Dose: per protocol.
Function: Stimulates granulocytes and monocytes.
Mechanism: GM-CSF receptor activation; sometimes used in recovery phases. -
Epoetin alfa or Darbepoetin alfa — Dose: individualized for symptomatic anemia not due to iron/B12/folate deficiency; risks/benefits reviewed carefully in cancer care.
Function: Raise hemoglobin in selected cases.
Mechanism: Erythropoiesis stimulation. -
Plerixafor — Dose: weight-based subcutaneous dosing for stem-cell mobilization in transplant settings.
Function: Helps move stem cells into bloodstream for collection.
Mechanism: CXCR4 inhibition. -
Intravenous immunoglobulin (IVIG) — Dose: per kg when severe hypogammaglobulinemia with recurrent infections is documented.
Function: Passive antibody support.
Mechanism: Replaces missing IgG to reduce infection risk.
(Notes: Thrombopoietin receptor agonists are generally not routine in AML induction because of concerns about stimulating blasts; decisions are specialist-only.)
Surgeries / Procedures (what they are; why done)
-
Central venous catheter/port placement
Procedure: A small device or tunneled line is placed into a large vein.
Why: Reliable access for chemotherapy, blood draws, and transfusions. -
Bone-marrow aspiration and biopsy
Procedure: A needle takes marrow samples from hip bone.
Why: Diagnose AML, track remission, check genetics/minimal residual disease. -
Lumbar puncture ± intrathecal chemotherapy
Procedure: A thin needle draws cerebrospinal fluid; medicine may be given into the space.
Why: To check/treat leukemia in the central nervous system if suspected or per protocol. -
Leukapheresis (selected cases)
Procedure: A machine removes white cells from blood.
Why: Emergency cytoreduction when white counts are dangerously high with leukostasis symptoms; role is individualized and often combined with chemo. PMCASH Publications -
Allogeneic hematopoietic stem-cell transplantation (HSCT)
Procedure: After high-intensity conditioning, donor stem cells are infused.
Why: Curative intent for eligible patients at high relapse risk; replaces diseased marrow with healthy donor cells.
Preventions
Primary risk reduction (before AML):
-
Avoid tobacco;
-
Minimize benzene and solvent exposure at work (proper ventilation/PPE);
-
Limit unnecessary ionizing radiation exposure;
-
Follow workplace safety for pesticides and industrial chemicals;
-
Manage obesity and diabetes risk (general health).
During treatment (infection and complication prevention):
- Hand hygiene, mask in crowds as advised, keep vaccinations up to date (inactivated only; timing per team);
- Food safety: cook meats/eggs well, avoid unpasteurized dairy, wash produce thoroughly;
- Keep central lines clean and dry;
- Follow tumor lysis prophylaxis if you’re high risk (fluids, uric-acid control as ordered);
- Call promptly for fever ≥38.0°C (100.4°F), bleeding, chest pain, or confusion. CDCNCBI
When to see doctors
Call or go to emergency care now if you have:
• Fever ≥38.0°C (100.4°F); chills/rigors;
• Shortness of breath, chest pain, sudden dizziness or fainting;
• New confusion, severe headache, trouble speaking, or vision changes;
• Uncontrolled bleeding (nose, gums), black stools, or many new bruises;
• Severe abdominal pain, little or no urine, or very rapid swelling/weight gain (possible tumor lysis or fluid overload).
Contact your team within 24 hours for:
• New mouth sores, sore throat, cough;
• Painful urination, diarrhea, or vomiting that won’t stop;
• Redness, pain, or discharge at your line/port site;
• New rash or severe fatigue.
Routine: keep all lab checks, transfusion visits, and chemo days as scheduled.
What to Eat” and “What to Avoid
What to eat (focus on safety and strength):
-
Well-cooked proteins (eggs fully cooked; chicken, fish, and meat to safe internal temperatures).
-
Pasteurized dairy (yogurt, milk, cheese) if tolerated.
-
Well-washed or cooked fruits/vegetables; peel when possible during neutropenia.
-
Soft, high-protein foods if mouth is sore (scrambled eggs, tofu, nut butters if safe, smoothies made with pasteurized ingredients).
-
Hydrating fluids (water, oral rehydration solutions, clear soups).
What to avoid (especially during neutropenia):
- Raw or undercooked meats, fish (sushi), or eggs;
- Unpasteurized milk, cheeses, or juices;
- Salad bars, buffets, and deli meats unless heated steaming hot;
- Unwashed produce;
- Alcohol beyond minimal amounts (or as your team advises—often none during chemo).
Note on “neutropenic diets”: Modern evidence does not show that very strict “neutropenic diets” prevent infections; most centers now stress safe food handling rather than broad bans—follow your hospital’s advice. FrontiersCDCPMC
-
Hyperleukocytosis & leukostasis: If white counts are extremely high with breathing or brain symptoms, urgent cytoreduction is needed (hydroxyurea, chemo ± leukapheresis). PMCASH Publications
-
Tumor lysis syndrome (TLS): Prevention includes IV fluids and uric-acid control (allopurinol for lower risk; rasburicase for higher risk or active TLS). NCBIMedscape
Frequently Asked Questions
-
Is AML curable?
Yes, many patients achieve long-term remission or cure, especially with appropriate chemo ± targeted therapy and, for some, stem-cell transplant. -
How fast must treatment start?
AML grows quickly. Once stabilized (e.g., infections, TLS risk addressed), induction chemo typically begins promptly. -
What is “7+3”?
A standard induction: cytarabine for 7 days plus an anthracycline for 3 days. It aims to put AML into remission. Cancer.gov -
What if I’m older or have other illnesses?
Lower-intensity plans like azacitidine/decitabine plus venetoclax are often used and can be effective. U.S. Food and Drug Administration -
What is “targeted therapy”?
Pills that block specific mutations (FLT3, IDH1, IDH2) or pathways; they’re added based on your leukemia’s genetics. PMCU.S. Food and Drug Administration+1FDA Access Data -
Will I need a transplant?
Some do, especially if relapse risk is high. Your team uses risk scores and genetic tests to decide. -
How are side effects controlled?
With transfusions, antibiotics/antivirals/antifungals, growth-factor support, nausea control, mouth care, and close labs. -
Can I exercise?
Yes—light, safe activity is often encouraged. Stop for fever, dizziness, bleeding, or if the team says to pause. -
What about diet?
Focus on protein, fluids, and safe food handling. Avoid raw meats/eggs and unpasteurized products. Strict “neutropenic diets” are no longer universally recommended. FrontiersCDC -
Can supplements help?
Only if your team approves. Many supplements interact with chemo. Correcting deficiencies (e.g., vitamin D) may help overall health. -
What is leukapheresis?
A machine temporarily removes excess white cells in emergencies like leukostasis; it’s an adjunct to chemo, not a cure. PMC -
What is tumor lysis?
When many cancer cells die at once, releasing contents that can strain kidneys and the heart; fluids and medicines like allopurinol or rasburicase reduce risk. NCBI -
How long is treatment?
Induction (weeks), then consolidation cycles over months; some receive maintenance or proceed to transplant. -
Can I get vaccinated?
Inactivated vaccines may be given at specific times; live vaccines are avoided. Timing is coordinated by your oncology team. -
Should I seek a clinical trial?
Trials can provide access to new therapies. Ask early; trials exist for many AML subtypes.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 07, 2025.
